FINWIRES · TerminalLIVE
FINWIRES

$IOVA

4 stories mentioning IOVAUpdated 45d ago

Every FINWIRES story that references IOVA, newest first.

Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA$TRDA
Sectors

Sector Update: Health Care Stocks Decline in Afternoon Trading

Health care stocks declined Thursday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.6%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.2% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA
Sectors

Sector Update: Health Care

Health care stocks declined Thursday afternoon with the NYSE Health Care Index shedding 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell 14% after the company's Q1 loss narrowed less than expected and revenue missed estimates.

$IOVA
Wire

Iovance Biotherapeutics Shares Drop After Q1 Results Miss

Iovance Biotherapeutics (IOVA) shares dropped over 11% in Thursday trading after the company reported lower-than-expected Q1 results.The company reported a Q1 net loss of $0.19 per diluted share, narrowing from a loss of $0.36 a year earlier.Analysts polled by FactSet expected a loss of $0.15.Revenue for the quarter ended March 31 was $71.4 million, up from $49.3 million a year earlier.Analysts expected revenue of $77.8 million.The company said it expects its cash position to fund operations well into 2028.Iovance said it expects total product revenue of $86 million to $88 million for Q2, and $350 million to $370 million for 2026.Price: $3.62, Change: $-0.47, Percent Change: -11.49%

$IOVA

Track with the FINWIRES app suite